ESSA Pharma Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de ESSA Pharma disminuyan a un ritmo anual de 12%, mientras que sus ingresos anuales crecerán a un ritmo de 73.8% por año. Se espera que el BPA disminuya en un 9.6% al año.

Información clave

-12.0%

Tasa de crecimiento de los beneficios

-9.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	21.2%
Tasa de crecimiento de los ingresos	73.8%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	16 Feb 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:EPIX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2026	6	-83	-118	N/A	4
9/30/2025	N/A	-58	-80	N/A	4
9/30/2024	N/A	-36	-39	N/A	4
12/31/2023	N/A	-26	-22	-22	N/A
9/30/2023	N/A	-27	-20	-20	N/A
6/30/2023	N/A	-27	-22	-22	N/A
3/31/2023	N/A	-29	-25	-25	N/A
12/31/2022	N/A	-33	-27	-27	N/A
9/30/2022	N/A	-35	-28	-28	N/A
6/30/2022	N/A	-37	-28	-28	N/A
3/31/2022	N/A	-37	-28	-28	N/A
12/31/2021	N/A	-39	-27	-27	N/A
9/30/2021	N/A	-37	-25	-25	N/A
6/30/2021	N/A	-33	-22	-22	N/A
3/31/2021	N/A	-29	-19	-19	N/A
12/31/2020	N/A	-25	-18	-18	N/A
9/30/2020	N/A	-23	-17	-17	N/A
6/30/2020	N/A	-22	-18	-18	N/A
3/31/2020	N/A	-21	-17	-17	N/A
12/31/2019	N/A	-15	-14	-14	N/A
9/30/2019	N/A	-13	-12	-12	N/A
6/30/2019	N/A	-12	-9	-9	N/A
3/31/2019	N/A	-11	-10	-10	N/A
12/31/2018	N/A	-12	-10	-10	N/A
9/30/2018	N/A	-12	-10	-10	N/A
6/30/2018	N/A	-11	-11	-11	N/A
3/31/2018	N/A	-5	-13	-13	N/A
12/31/2017	N/A	-8	-13	-13	N/A
9/30/2017	N/A	-4	N/A	-17	N/A
6/30/2017	N/A	-7	N/A	-18	N/A
3/31/2017	N/A	-14	N/A	-16	N/A
12/31/2016	N/A	-8	N/A	-19	N/A
9/30/2016	N/A	-13	N/A	-15	N/A
6/30/2016	N/A	-8	N/A	-17	N/A
3/31/2016	N/A	-10	N/A	-18	N/A
12/31/2015	N/A	-12	N/A	-14	N/A
9/30/2015	N/A	-10	N/A	-13	N/A
6/30/2015	N/A	-11	N/A	-10	N/A
3/31/2015	N/A	-6	N/A	-5	N/A
12/31/2014	N/A	-3	N/A	-4	N/A
9/30/2014	N/A	-2	N/A	-2	N/A
6/30/2014	N/A	-1	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que EPIX siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que EPIX siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que EPIX siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que EPIX no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que EPIX no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de EPIX se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

ESSA Pharma Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate

ESSA Pharma Inc., Annual General Meeting, Mar 06, 2024

New major risk - Revenue and earnings growth

Independent Director recently bought US$135k worth of stock

New major risk - Share price stability

Independent Director recently bought US$420k worth of stock

ESSA Pharma Inc. Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat

ESSA Pharma Inc. Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans

New major risk - Financial position

High number of new directors

Essa Pharma Inc. Appoints Lauren Merendino to Its Board of Directors

Now 21% undervalued after recent price drop

Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)

Now 23% undervalued

Independent Director notifies of intention to sell stock

We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely

ESSA Pharma Inc., Annual General Meeting, Mar 09, 2023

ESSA Pharma Inc. Provides an Update on Its Clinical Collaboration with Janssen

Insufficient new directors

ESSA Pharma Inc. Announces Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat

ESSA Pharma Inc. Appoints Philip Kantoff to its Board of Directors

ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development

ESSA Pharma Inc. Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders

ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting

ESSA Pharma Inc., Annual General Meeting, Mar 09, 2022

ESSA Pharma Inc., Annual General Meeting, Mar 09, 2022

ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients

ESSA Pharma Inc. Enters into Clinical Collaboration and Supply Agreement with Astellas Pharma Inc. to Evaluate Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma Inc. has completed a Follow-on Equity Offering in the amount of $130.434786 million.

ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium

ESSA Pharma: Update Including Clinical Collaboration Agreement With Janssen

ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma and Janssen to test combo treatments in prostate cancer setting

ESSA Pharma EPS beats by $0.02

ESSA Pharma Inc. Announces Voluntary Delisting from the TSX-V

New 90-day low: US$6.10

Independent Chairman of the Board recently bought US$37k worth of stock

Essa Pharma Inc. Announces the Presentation of Data of ESSA's Clinical Candidate, EPI-7386, at the ESMO Virtual Congress 2020

New 90-day high - US$7.64

Independent Director recently bought US$551k worth of stock

New 90-day high - US$7.06

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento